1. People's Republic of China Stocks

  2. •

    Consumer Defensive

  3. •

    Packaged Foods
Sirio Pharma Co., Ltd.

Sirio Pharma Co., Ltd.

300791.SZ
Sirio Pharma Co., Ltd.CN flagShenzhen Stock Exchange
15.89
CNY
-0.05
- -
4.91BMarket Cap
Sirio Pharma Co., Ltd.
300791.SZ
(Shenzhen Stock Exchange)

Recent

price

15.89

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
19.34
3.45
5.84
7
6.38
6.8
7.79
8.24
11.75
13.87
13.95
10.05
Revenue per Share
- -
- -
- -
1.32
3.08
0.46
0.89
0.58
0.85
0.76
0.7
0.92
1.07
0.45
0.06
Basic EPS, GAAP
- -
- -
- -
-1.26
-0.75
-0.48
-0.25
0.26
0.32
-0.6
0.5
-0.22
0.51
0.42
-0.97
Free Cash Flow per Basic Share
- -
- -
- -
3.24
1.17
0.99
0.19
0.06
0.09
0.24
0.25
0.28
0.72
0.6
0.59
Dividend per Share
- -
- -
- -
2.86
1.32
1.88
2.77
3.17
3.43
4.11
4.56
5.23
5.77
5.85
6.03
Book Value per Share
- -
- -
- -
1.74
0.57
1.02
1.93
6.44
6.02
7.16
7.63
5.14
5.49
6.67
6.76
Tangible Book Value per Share
- -
- -
- -
43
228
228
228
247
304
304
304
305
304
306
305
Basic Weighted Avg Shares
554
699
779
824
786
1,330
1,595
1,580
2,067
2,369
2,507
3,582
4,211
4,263
3,062
Sales/Revenue/Turnover
11.62
11.72
11.18
10.68
6.78
11.86
15.9
10.24
14.75
12.45
10.34
11.01
10.43
7.71
6.48
Operating Margin (%)
16
19
27
29
32
48
55
72
80
104
132
257
239
258
- -
Depreciation Expense
45
55
61
56
704
104
203
143
257
232
212
281
325
137
19
Net Income, GAAP
16.63
16.93
17.2
20.33
24.93
20.13
11.79
9.16
17.5
17.47
15.6
12.07
10.94
- -
23.72
Effective Tax Rate (%)
8.19
7.81
7.89
6.82
89.51
7.84
12.74
9.02
12.45
9.79
8.47
7.85
7.72
3.2
0.61
Profit Margin (%)
-15
3
-128
-91
28
97
47
1,015
933
1,582
1,963
1,182
1,198
862
922
Working Capital
30
52
28
11
146
223
158
32
1
869
929
1,305
1,484
1,445
1,525
LT Debt
168
204
139
241
462
580
784
1,945
2,183
2,545
2,702
2,566
2,641
2,959
2,967
Total Equity
- -
21.8
22.51
17.04
5.38
12.87
20.21
8.97
11.73
8.6
6.19
9.14
9.49
- -
- -
Return on Invested Capital (%)
- -
23.18
25.62
20.29
133.18
15.16
23.05
15.92
26.34
15.18
11.16
14.3
13.65
- -
20.15
Return on Capital (%)
- -
36.1
45.44
50.73
333.11
28.57
38.29
20.12
28.18
20.22
16.09
18.84
19.43
7.72
1.02
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
239
284
LT Borrowings
- -
1,137
1,213
LT Finance Leases
- -
307
313
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
308
308
Market Capitalization
7,251
7,886
6,195

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
1,922
2,011
Cash, Cash Equivalents & STI
- -
600
669
Accounts Receivable, Net
- -
683
688
Inventories
- -
458
472
Total Current Liabilities
- -
1,060
1,090
Payables & Accruals
- -
- -
- -
ST Debt
- -
239
284
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
34.52%
6.54%
12.05%
Free Cash Flow
-100.2%
-193.73%
-16.74%
Net Income, GAAP
118.28%
-5.66%
-58%
Sales/Revenue/Turnover
19.65%
16.42%
1.23%
Total Cash Common Dividend
35.14%
68.18%
-16.66%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
952
1,039
1,058
1,163
4,211
2025
954
1,087
- -
972
4,263
2026
1,003
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
- -
- -
- -
1.07
2025
0.23
- -
- -
- -
0.45
2026
0.16
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.72
2025
0.01
- -
- -
- -
0.6
2026
0.01
- -
- -
- -
- -
Similar Companies
Savencia S.A. (BNGRF)
PlantFuel Life Inc. (PLFLF)
Thai Union Group Public Company Limited (THYG.F)
Springsnow Food Group Co., Ltd. (605567.SS)
RFG Holdings Limited (RFG.JO)
Synlait Milk Limited (SMLKF)
Business
Sirio Pharma Co., Ltd. serves as a prominent contract development and manufacturing organization for the global nutritional and health food sector. The company specializes in the creation and production of a diverse array of nutritional products, encompassing traditional and plant-based softgels, innovative nutraceutical gummies, probiotic formulations, tablets, powders, hard capsules, and functional liquids. Beyond manufacturing, it provides comprehensive, end-to-end solutions, including product research, development, custom packaging, logistics, and marketing assistance. Established in 1993, Sirio Pharma is headquartered in Shantou, China, with an expanding international presence, including manufacturing sites in the U.S. and Europe, supporting its "globally local" strategy. The company has demonstrated consistent growth, with its 2024 annual revenue reaching RMB 4.211 billion, reflecting a 17.56% year-over-year increase.